Seattle Genetics, Inc. (NASDAQ:SGEN) insider Clay B. Siegall sold 25,000 shares of the firm’s stock in a transaction on Tuesday, August 21st. The stock was sold at an average price of $74.95, for a total transaction of $1,873,750.00. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Clay B. Siegall also recently made the following trade(s):

  • On Thursday, August 9th, Clay B. Siegall sold 18,831 shares of Seattle Genetics stock. The stock was sold at an average price of $72.71, for a total transaction of $1,369,202.01.
  • On Monday, July 9th, Clay B. Siegall sold 18,832 shares of Seattle Genetics stock. The stock was sold at an average price of $69.07, for a total transaction of $1,300,726.24.
  • On Friday, June 8th, Clay B. Siegall sold 18,832 shares of Seattle Genetics stock. The stock was sold at an average price of $65.12, for a total transaction of $1,226,339.84.

SGEN opened at $74.59 on Friday. Seattle Genetics, Inc. has a fifty-two week low of $47.17 and a fifty-two week high of $76.48. The firm has a market capitalization of $11.96 billion, a price-to-earnings ratio of -84.07 and a beta of 1.70.

Seattle Genetics (NASDAQ:SGEN) last released its quarterly earnings data on Thursday, July 26th. The biotechnology company reported $0.47 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.34) by $0.81. Seattle Genetics had a negative net margin of 7.75% and a negative return on equity of 21.01%. The company had revenue of $170.20 million during the quarter, compared to analysts’ expectations of $141.07 million. During the same quarter in the previous year, the company earned ($0.39) earnings per share. The firm’s revenue for the quarter was up 57.3% on a year-over-year basis. equities research analysts expect that Seattle Genetics, Inc. will post -1.12 EPS for the current fiscal year.

Several research analysts recently issued reports on SGEN shares. HC Wainwright reissued a “buy” rating and set a $77.00 target price on shares of Seattle Genetics in a report on Thursday, July 12th. JPMorgan Chase & Co. raised their target price on shares of Seattle Genetics from $66.00 to $77.00 and gave the stock an “overweight” rating in a report on Friday, July 27th. Barclays reissued a “buy” rating and set a $80.00 target price on shares of Seattle Genetics in a report on Friday, July 27th. BidaskClub raised shares of Seattle Genetics from a “sell” rating to a “hold” rating in a report on Wednesday, May 16th. Finally, Royal Bank of Canada reissued a “buy” rating and set a $75.00 target price on shares of Seattle Genetics in a report on Friday, July 27th. Six analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $71.64.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Baker BROS. Advisors LP increased its holdings in Seattle Genetics by 3.0% in the second quarter. Baker BROS. Advisors LP now owns 51,046,060 shares of the biotechnology company’s stock valued at $3,388,948,000 after buying an additional 1,470,651 shares in the last quarter. BlackRock Inc. increased its stake in shares of Seattle Genetics by 5.1% during the second quarter. BlackRock Inc. now owns 8,928,665 shares of the biotechnology company’s stock worth $592,774,000 after purchasing an additional 435,702 shares in the last quarter. Point72 Asset Management L.P. purchased a new stake in shares of Seattle Genetics during the second quarter worth about $83,840,000. First Trust Advisors LP increased its stake in shares of Seattle Genetics by 18.0% during the second quarter. First Trust Advisors LP now owns 1,042,574 shares of the biotechnology company’s stock worth $69,216,000 after purchasing an additional 159,401 shares in the last quarter. Finally, Blair William & Co. IL increased its stake in shares of Seattle Genetics by 5.3% during the first quarter. Blair William & Co. IL now owns 692,242 shares of the biotechnology company’s stock worth $36,232,000 after purchasing an additional 34,744 shares in the last quarter.

About Seattle Genetics

Seattle Genetics, Inc, a biotechnology company, focuses on the development and commercialization of targeted therapies for the treatment of cancer worldwide. It markets ADCETRIS, an antibody-drug conjugate for the treatment of relapsed Hodgkin lymphoma and relapsed systemic anaplastic large cell lymphoma.

Featured Article: What are the Different Types of Leveraged Buyouts?

Insider Buying and Selling by Quarter for Seattle Genetics (NASDAQ:SGEN)

Receive News & Ratings for Seattle Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seattle Genetics and related companies with MarketBeat.com's FREE daily email newsletter.